Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies.

May, Heidi T; Muhlestein, Joseph B; Ma, Yuhui; López, J Antonio G; Coll, Blai; Nelson, John

May, Heidi T; Muhlestein, Joseph B; Ma, Yuhui; López, J Antonio G; Coll, Blai; Nelson, John.

Afiliación

May HT; Intermountain Heart Institute, Intermountain Medical Center, Murray, UT, USA. heidi.may@imail.org.
Muhlestein JB; Intermountain Heart Institute, Intermountain Medical Center, Murray, UT, USA.
Ma Y; Department of Medicine, University of Utah, Salt Lake City, UT, USA.
López JAG; Amgen Inc., Thousand Oaks, CA, USA.
Coll B; Amgen Inc., Thousand Oaks, CA, USA.
Nelson J; Amgen Inc., Thousand Oaks, CA, USA.

Cardiol Ther ; 8(1): 91-102, 2019 Jun.

Article en En | MEDLINE | ID: mdl-30852766

Palabras clave

Evolocumab; Mixed dyslipidemia; Non-HDL-C; PCSK9; Remnant lipoprotein; Threshold; VLDL

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cardiol Ther Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google